4CPS-154 Abstract withdrawn
| Autor: | S. García Castañón, D. González Benito, C. Blanco Cristóbal, M.D. Martínez Gago, F.J. Cepeda Piorno, E. Fernández Rodríguez, V. García Moreira, R. Escobar Conesa |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
musculoskeletal diseases
Drug medicine.medical_specialty Necrosis biology business.industry Immunogenicity media_common.quotation_subject Standard treatment Gastroenterology Infliximab Regimen Internal medicine medicine Adalimumab biology.protein medicine.symptom Antibody skin and connective tissue diseases business medicine.drug media_common |
| Zdroj: | Section 4: Clinical Pharmacy Services. |
| DOI: | 10.1136/ejhpharm-2019-eahpconf.303 |
| Popis: | Background The introduction of anti-tumour necrosis factor alpha such as infliximab and adalimumab has improved the treatment of digestive and rheumatic inflammatory diseases. However, a percentage of these patients have anti-infliximab or anti-adalimumab antibodies that are associated with failure in treatment, causing greater morbidity and relapse of the disease. Purpose To determine serum concentrations and immunogenicity of infliximab and adalimumab that contribute to the clinical status examination of patients and to make appropriate therapeutic decisions. Material and methods We reviewed the results obtained during 1 year in 100 patients (48 females and 52 males) in treatment with infliximab (n=48) and adalimumab (n=52). In the infliximab regimen, 32 were on standard therapy (5 mg/kg/8 weeks), 10 were on intensified therapy and six with spaced treatment. For adalimumab, 36 were on follow-up standard treatment: 40 mg/2 weeks, 14 were on intensified treatment and two with spaced treatment. Quantification was performed after blood extraction at the prior time to infusion, by enzyme immunoassay. Optimal concentrations were considered 5–8 µg/ml for adalimumab and 3–7 µg/ml for infliximab in digestive pathologies and >3 µg/ml in rheumatic diseases. The anti-drug antibodies were analysed in patients with concentrations 2 positive, 1–2 weak positive and Results The mean concentration for infliximab was 2.13 µg/ml, with 10 determinations>7 µg/ml, 14 between 3–7 µg/ml and 37 Conclusion The therapeutic decision, based on the patient’s clinical status and the concentration of drug and antibodies, was that the drug was changed in patients with subtherapeutic levels and positive antibodies. Meanwhile, in patients with subtherapeutic levels and antibodies with weak or negative positivity, treatment was intensified. References and/or acknowledgements Acknowledgements Carlos Blanco Cristobal. No conflict of interest. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|